ArticleCell death & disease2018
The natural compound GL22, isolated from Ganoderma mushrooms, suppresses tumor growth by altering lipid metabolism and triggering cell death.
Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Integrative analysis of metabolome and transcriptome reveals new insights into the formation and regulation of major components ofMicrobiology spectrum · 2026Article
- Bioactive compounds of Ganoderma species: molecular mechanisms and therapeutic potential in cancer and metabolic disorders.World journal of microbiology & biotechnology · 2025Review
- Recent Advances in the Use ofPharmaceutics · 2025Review
- Characterization and Functional Analysis of a Novel Fungal Immunomodulatory Protein Gene fromInternational journal of molecular sciences · 2025Article
- Shikonin a potent phytotherapeutic: a comprehensive review on metabolic reprogramming to overcome drug resistance in cancer.Molecular biology reports · 2025Review
- Extraction Optimization and Bioactivity of Polysaccharides fromPharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting lipid reprogramming in the tumor microenvironment by traditional Chinese medicines as a potential cancer treatment.Heliyon · 2024Review
- Therapeutic Potential of Fungal Terpenes and Terpenoids: Application in Skin Diseases.Molecules (Basel, Switzerland) · 2024Review
- Exploring Nutrient Profiles, Phytochemical Composition, and the Antiproliferative Activity ofFoods (Basel, Switzerland) · 2024Article
- Crosstalk Between circRNA and Tumor Microenvironment of Hepatocellular Carcinoma: Mechanism, Function and Applications.OncoTargets and therapy · 2024Review
- Telomere-to-Telomere Genome Assembly of Tibetan Medicinal MushroomJournal of fungi (Basel, Switzerland) · 2023Article
- Mushroom-Derived Compounds as Metabolic Modulators in Cancer.Molecules (Basel, Switzerland) · 2023Review
- Lipid metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy.Journal of Cancer · 2023Review
- Evaluation of the acute toxicity and 28-days subacute toxicity of the alcoholic extract fromFood science & nutrition · 2023Article
- Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.Nutrients · 2022Review
- Whole-genome assembly of Ganoderma leucocontextum (Ganodermataceae, Fungi) discovered from the Tibetan Plateau of China.G3 (Bethesda, Md.) · 2021Article
- Proteomic Research on the Antitumor Properties of Medicinal Mushrooms.Molecules (Basel, Switzerland) · 2021Review
- Natural Products Targeting the Mitochondria in Cancers.Molecules (Basel, Switzerland) · 2020Review
- Berberine Suppressed Tumor Growth through Regulating Fatty Acid Metabolism and Triggering Cell Apoptosis via Targeting FABPs.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Ganoderiol F purified fromCell cycle (Georgetown, Tex.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer cells rewire their metabolism to satisfy the demands of uncontrolled proliferation and survival. The reprogramming of lipid metabolism supports tumor growth, metastasis, and therapy-resistance. Therefore, targeting lipid metabolic reprogramming is a potential cancer treatment strategy. We recently isolated the novel natural triterpene GL22 from Ganoderma leucocontextum, a traditional Chinese medicine. Here, we show that GL22 significantly inhibits the growth of the liver cancer cell line Huh7.5 in vitro and of Huh7.5-derived tumor xenografts in vivo. We further find that GL22 induces mitochondrial dysfunction and cell death in Huh7.5 cells, in part due to fatty acid immobilization and loss of the mitochondrial lipid cardiolipin, which has vital structural and metabolic functions. Importantly, we demonstrate that GL22 treatment decreases the expression of fatty acid-binding proteins (FABPs), which likely underlies the loss of cardiolipin, mitochondrial dysfunction, and cell death. The over-expressions of FABPs prevented the GL22-induced cell death, loss of cardiolipin, decrease of ATP production, and reduction of oxygen consumption rate in Huh7.5 cells. Our results support targeting lipid metabolism via manipulating FABPs as a cancer treatment strategy, and promote Chinese medicine as an important source of novel anticancer drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.